Capecitabine
Back to searchMolecule Structure
Scientific Name
Capecitabine
Description of the Drug
Capecitabine is a nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01101
http://www.drugbank.ca/drugs/DB01101
Brand Name(s)
Capecitabine, Xeloda
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Alkem Laboratories Ltd, Msn Laboratories Private Ltd, Hoffmann La Roche Inc, Reliance Life Sciences Pvt Ltd, Sun Pharmaceutical Industries Ltd, Rising Pharma Holding Inc, Shilpa Medicare Ltd, Eugia Pharma Specialities Ltd, Accord Healthcare Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| RNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311222 |
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
| Thymidylate synthase | SINGLE PROTEIN | INHIBITOR | CHEMBL1952 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8153 | |
| PharmGKB | PA448771 | |
| Human Metabolome Database | HMDB0015233 | |
| DrugBank | DB01101 | |
| PubChem: Thomson Pharma | 14925873 | 14828191 |
| PubChem | 60953 | |
| Mcule | MCULE-2851259722 | |
| LINCS | LSM-5705 | |
| Nikkaji | J949.163E | |
| EPA CompTox Dashboard | DTXSID3046451 | |
| DrugCentral | 480 | |
| Brenda | 148223 | 38000 |
| ChemicalBook | CB1324457 | |
| Guide to Pharmacology | 6799 | |
| rxnorm | CAPECITABINE | XELODA |
| PubChem: Drugs of the Future | 12014895 | |
| KEGG Ligand | C12650 | |
| ChEBI | 31348 | |
| ZINC | ZINC000003806413 |
